Barclays has initiated coverage on IDEAYA Biosciences Inc (IDYA) with an Overweight rating as of September 3, 2025. This marks the firm's first assessment of the biotechnology company, which focuses on oncology-oriented precision medicine. IDEAYA, headquartered in South San Francisco, California, is engaged in discovering and developing targeted therapeutics based on molecular diagnostics.
The company has a market capitalisation of $2.9 billion and reported a trailing twelve-month earnings per share (EPS) of -1.85. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), and IDE849 (DLL3), among others. IDEAYA's upcoming earnings are scheduled for August 3, 2026, with an estimated EPS of -1.00 and revenue of $6.1 million.
Analyst ratings, such as this one from Barclays, reflect professional opinions derived from research and financial models. While they offer insights, these assessments are based on assumptions that may not materialise as anticipated. Therefore, investment decisions should consider a range of factors, including company fundamentals and market trends, rather than relying solely on analyst views.
As of November 1, 2025, the consensus among analysts is a Buy, with 9 Strong Buy, 13 Buy, and 3 Hold ratings. Recent actions include a Market Outperform initiation by JMP Securities and an Overweight rating maintained by JP Morgan, indicating a generally positive outlook for IDEAYA in the current market landscape.